The Korea Herald BusinessDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 10:21:28(首尔 11:21)·⟳ 抓取 10:22:26 +58s·⚡ 决策 10-15 10:23:24 +58s·12.7 天前
Celltrion 将在 UEG Week 2026 展示 Remsima SC 等 IBD 产品既有临床数据，属常规学术推广
这是一条药企在大型消化科学术会议前的常规参展新闻稿：展示已发表/既有临床数据和真实世界用药经验，配合欧洲直销网络做品牌推广；不含新试验结果、监管节点、订单或财务指引，71%/24% 份额为旧的一季度 IQVIA 数据。无预期差、无方向性 edge，不具备交易价值。
📄 原文The Korea Herald Business↗ 原文
Celltrion to highlight Remsima SC clinical data at UEG Week 2026
Celltrion said Thursday it will present clinical data on its autoimmune disease treatment Remsima SC and promote its br…
不做 Celltrion（068270.KS）
纯学术会议参展/营销预告，只展示既有数据，无新临床、监管、订单或指引增量，无预期差与可交易 edge；韩股虽盘中可成交，但没有值得下单的催化
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Celltrion 预告在 UEG Week 2026 上宣讲 Remsima SC 等已上市 IBD 产品的既有数据，属常规学术营销而非新临床/监管/商业增量，对股价无可交易催化，回避。
🔎 新鲜度:最早出现 2026-10-15 · 扩散 low · price-in 风险 low ↗
主要风险
- 若会议期间公布此前未披露的优效性头对头数据或重大监管/商业进展，可能构成新事件，需届时单独研判，本新闻稿本身不包含该信息
先例如何影响了这次决策
对本次决策的影响:未产生任何交易参数；直接判定 AVOID
方向:不适用：无新增事实的常规会议营销新闻稿不具备事件研究前提，强行检索'医药公司学术会议参展'先例只会引入无因果噪声
涨幅量级:不足以校准任何涨跌幅，未设定 tp/sl
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`celltrion ibd portfolio steqeyma yuflyma europe symposium inflammatory bowel disease | celltrion remsima sc ueg week 2026 barcelona clinical data presentation | 셀트리온 램시마sc ueg week`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen
原文全文
展开原文 · 2,086 字
Celltrion said Thursday it will present clinical data on its autoimmune disease treatment Remsima SC and promote its broader inflammatory bowel disease (IBD) drug portfolio at UEG Week 2026 in Barcelona, Spain, from Saturday to Tuesday.
The annual United European Gastroenterology Week is a major international conference for digestive disease specialists, drawing more than 12,100 participants from 115 countries last year.
The Korean biopharmaceutical company will showcase its Remsima intravenous and subcutaneous formulations, including a liquid IV version launched in Europe earlier this year, alongside two other IBD treatments, Steqeyma (ustekinumab) and Yuflyma (adalimumab).
On Sunday, Celltrion will host a symposium on the clinical use of subcutaneous infliximab, chaired by Peter M. Irving, a professor at King's College London.
Specialists will discuss clinical findings and treatment experiences involving patients with Crohn's disease and ulcerative colitis, including the use of Remsima SC from early treatment through long-term disease management.
Two additional expert sessions will examine real-world evidence supporting Remsima SC monotherapy and clinical considerations when switching Crohn's disease patients to the subcutaneous formulation.
The presentations will be led by Irina Blumenstein of University Hospital Frankfurt and Gionata Fiorino of San Camillo-Forlanini Hospital in Rome, respectively.
Celltrion is seeking to build on its position in Europe's IBD treatment market. According to first-quarter IQVIA data cited by the company, Remsima IV and SC held a combined 71 percent market share in Europe, while Yuflyma accounted for 24 percent.
The company plans to use its established European direct-sales network to expand sales across its IBD portfolio.
"We plan to present a broad range of clinical data and real-world prescribing experience to healthcare professionals worldwide to highlight the value of Celltrion's IBD treatments, including Remsima SC," said Ha Tae-hun, senior vice president and head of Europe at Celltrion.
yejinlim@heraldcorp.com
The annual United European Gastroenterology Week is a major international conference for digestive disease specialists, drawing more than 12,100 participants from 115 countries last year.
The Korean biopharmaceutical company will showcase its Remsima intravenous and subcutaneous formulations, including a liquid IV version launched in Europe earlier this year, alongside two other IBD treatments, Steqeyma (ustekinumab) and Yuflyma (adalimumab).
On Sunday, Celltrion will host a symposium on the clinical use of subcutaneous infliximab, chaired by Peter M. Irving, a professor at King's College London.
Specialists will discuss clinical findings and treatment experiences involving patients with Crohn's disease and ulcerative colitis, including the use of Remsima SC from early treatment through long-term disease management.
Two additional expert sessions will examine real-world evidence supporting Remsima SC monotherapy and clinical considerations when switching Crohn's disease patients to the subcutaneous formulation.
The presentations will be led by Irina Blumenstein of University Hospital Frankfurt and Gionata Fiorino of San Camillo-Forlanini Hospital in Rome, respectively.
Celltrion is seeking to build on its position in Europe's IBD treatment market. According to first-quarter IQVIA data cited by the company, Remsima IV and SC held a combined 71 percent market share in Europe, while Yuflyma accounted for 24 percent.
The company plans to use its established European direct-sales network to expand sales across its IBD portfolio.
"We plan to present a broad range of clinical data and real-world prescribing experience to healthcare professionals worldwide to highlight the value of Celltrion's IBD treatments, including Remsima SC," said Ha Tae-hun, senior vice president and head of Europe at Celltrion.
yejinlim@heraldcorp.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
aef73f32ce· 2026-10-15 10:23 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前